In this study, we demonstrate a novel immune defect in LPS-activated human CF macrophages and show that this disease phenotype is reversible by the actions of CFTR modulator therapies, thus also underlying the role of intrinsic CFTR dysfunction in causing dysregulation of immune function in CF myeloid cells. Here, CFTR is linked to cystic fibrosis.